Paraneoplastic AQP4-IgG–Seropositive Neuromyelitis Optica Spectrum Disorder Associated With Teratoma

A Case Report and Literature Review

Ryotaro Ikeguchi, MD, PhD, Yuko Shimizu, MD, PhD, Ayato Shimomura, MD, Miki Suzuki, MD, PhD, Kanoko Shimoji, MD, Takashi Motohashi, MD, Tomoko Yamamoto, MD, PhD, Noriyuki Shibata, MD, PhD, and Kazuo Kitagawa, MD, PhD

Neurol Neuroimmunol Neuroinflamm 2021;8:e1045. doi:10.1212/NXI.0000000000001045

Correspondence
Dr. Shimizu
shimizu.yuko@twmu.ac.jp

Abstract

Objectives
To assess a case of paraneoplastic aquaporin-4 (AQP4)-immunoglobulin G (IgG)–seropositive neuromyelitis optica spectrum disorder (NMOSD) associated with teratoma and determine whether it is a paraneoplastic neurologic disorder.

Methods
A single case study and literature review of 5 cases.

Results
A 27-year-old woman presented with diplopia, facial nerve palsy, paraplegia, sensory dysfunction of lower limbs, dysuria, nausea, and vomiting. Spinal cord MRI detected an extensive longitudinal lesion in the spinal cord, and brain MRI detected abnormal lesions in the right cerebral peduncle and tegmentum of the pons. CSF analysis revealed positive oligoclonal IgG bands (OCBs). The patient tested positive for AQP4-IgG, confirming a diagnosis of NMOSD. An abdominal CT scan detected an ovarian tumor. After steroid therapy and tumor removal, the patient progressively improved, with only mild sensory dysfunction. Histopathologic analysis of the tumor revealed a teratoma and the presence of glial fibrillary acidic protein (GFAP)+ neural tissue with AQP4 immunoreactivity, accompanied by lymphocyte infiltration. Including the present case, there have been 6 reported cases of AQP4-IgG–seropositive NMOSD associated with ovarian teratoma (mean onset age, 32.7 years). Of these patients, 5 (83%) presented with nausea and/or vomiting, positive OCB, and dorsal brainstem involvement. Pathologic analyses of the teratoma were available in 5 cases, including the present case, revealing neural tissue with AQP4 immunoreactivity and lymphocyte infiltration in all cases.

Conclusions
This study suggests that ovarian teratoma may trigger the development of AQP4-IgG–seropositive NMOSD. Further studies are needed to elucidate the pathogenesis of teratoma-associated NMOSD.

From the Department of Neurology (R.I., Y.S., A.S., M.S., K.K.), Tokyo Women’s Medical University; Department of Gynecology (K.S., T.M.), Tokyo Women’s Medical University; and Department of Pathology (T.Y., N.S.), Tokyo Women’s Medical University, Tokyo, Japan.

Go to Neurology.org/NN for full disclosures. Funding information is provided at the end of the article.

The Article Processing Charge was funded by the authors.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
Neuromyelitis optica spectrum disorder (NMOSD), an autoimmune disease of the CNS, is characterized by optic neuritis and myelitis. Aquaporin-4 antibodies (AQP4-immunoglobulin G [IgG]) have been detected in 80% of patients with NMOSD. Patients with malignancies can develop various neurologic disorders, including the paraneoplastic neurologic disorder (PND) induced by malignancy-associated autoimmune mechanisms.1 Recently, malignancies (such as breast and lung cancers) have been reported to trigger NMOSD through a paraneoplastic mechanism.2-4 In addition, there are several case reports of AQP4-IgG–seropositive NMOSD associated with teratomas.5-7 However, the relationship between teratoma and the development of NMOSD remains unclear.

This study describes a case of paraneoplastic NMOSD with a teratoma containing GFAP+ neural tissue with AQP4 immunoreactivity and lymphocyte infiltration. Furthermore, we determine the clinical features of teratoma-associated NMOSD by reviewing 5 previously reported cases.

Methods
This is a single case study and literature review. Written informed consent was obtained from the patient. For the literature review, previously reported cases were systematically selected from PubMed using the key terms “teratoma,” “NMOSD,,” and “paraneoplastic.” Three case reports (5 cases) were identified and reviewed.

Data Availability
Anonymized data, for replicating the procedures, are available on reasonable request.

Case Report
A 27-year-old Chinese woman presented with chest and back pain a week after an upper respiratory tract infection. She was admitted to the hospital after developing diplopia, right facial nerve palsy, paraplegia, sensory dysfunction in the lower limbs, dysuria, nausea, and vomiting. MRI revealed an extensive dorsal brainstem lesion (1 with area postrema lesion). In the subsequent 16 months showed that the patient did not relapse, despite presenting with mild dysesthesia at the last neurologic examination.

Discussion
Generally, 3%–5% of NMOSDs are considered PND.2,3 Paraneoplastic NMOSD associated with cancer can be
mediated by intratumoral neural tissue expressing AQP4, triggering AQP4-IgG–related autoimmunity (intratumoral AQP4 is considered as an antigen). Among the discussed cases, we identified several common clinical features as explained below.

First, there was a high frequency of nausea and/or vomiting, consistent with a previous study of paraneoplastic NMOSD (nausea and vomiting were observed in 41.2% of paraneoplastic NMOSD and 6.6% in nonparaneoplastic NMOSD). These are known symptoms of NMOSD (also called area postrema syndrome of the dorsal medulla). Although the involvement of the area postrema was described in only 1 case, a dorsal brainstem close to the area postrema lesion was observed in 5 of 6 cases. The area postrema is a vomiting center located in the caudal and dorsal brainstem, which lacks a blood-brain barrier and features the high expression of AQP4. These characteristics suggest that the area postrema is affected by antibody-related autoimmunity in NMOSD.

Second, we noted a high frequency of OCB positivity (5/6) compared with that of nonparaneoplastic NMOSD, which is normally around 15%. A high frequency of OCB positivity suggests significantly increased production of IgGs in the CNS. The OCB positivity rate is also low (0/12) in the reported paraneoplastic NMOSD cases associated with tumors other than teratoma. Therefore, we speculate that intrathecal humoral immunity is strongly involved in the pathogenesis of NMOSD associated with teratoma.

Third, histopathologic analyses of the teratomas revealed several common features. Although the type of infiltrative lymphocytes in the neural tissue component was variable, GFAP+ neural tissue (glial component) with AQP4 immunoreactivity and infiltration of lymphocytes were consistent in all 5 cases. Most of the teratomas (96%) from patients with anti-NMDAR encephalitis (the most common form of PND) contained a neural tissue component compared with 38% of sporadic teratomas, and they exhibited higher lymphocyte infiltration frequency into the neural tissue. These findings suggest that teratomas featuring AQP4+ neural tissue accompanied by infiltrating lymphocytes contribute to NMOSD development. In contrast to a previous study, intratumoral complement immunoreactivity was observed in this case. However, complement immunoreactivity has been observed even in sporadic teratomas (62.5%). Therefore, further study is needed to elucidate the contribution of the complement system in NMOSD associated with teratoma.

Another common feature is the negative conversion of AQP4-IgG after tumor removal, which was evident in 3 of 5 cases. Although AQP4-IgG was found in the present case at the last follow-up, the titer kept decreasing after tumor removal (8.7 U/mL, assessed by ELISA). The conversion may also be due to the effect of the immunotherapies; however, our finding also suggests that paraneoplastic autoimmunity is involved in NMOSD associated with teratoma.

Finally, in this article, 3 of 6 (50%) patients who developed NMOSD were younger than 30 years. Although the age at...
onset of nonparaneoplastic NMOSD is typically around 35–45 years, similar to that of NMOSD associated with teratoma, the younger onset cases may reflect the tumorigenesis of teratoma. The median onset age of paraneoplastic NMOSD (associated with other cancers) was greater (55 years) than that of non-paraneoplastic NMOSD (40 years), which can be attributed to the age at tumor onset in paraneoplastic NMOSD. Therefore, we hypothesize that the age at onset of NMOSD associated with teratoma also correlates with the age at onset of teratoma.

A previous study on autoimmune GFAP astrocytopathy, a newly recognized CNS disease with CSF GFAP-α-IgG positivity, showed that multiple tumors were found in 22% of patients diagnosed with this disease. Although GFAP-α-IgG was negative in the present case, several common characteristics between NMOSD associated with teratoma and autoimmune GFAP astrocytopathy were observed. Among tumors that are found in cases of autoimmune GFAP astrocytopathy, ovarian teratoma is the most common (approximately 60% of tumors). In addition, ovarian teratoma from a patient with autoimmune GFAP astrocytopathy demonstrated GFAP staining. Moreover, autoimmune GFAP astrocytopathy showed high OCB positivity (54%). Of interest, in addition to GFAPα-IgG, coexistence of AQP4-IgG and/or anti-NMDAR antibody was observed in more than half of the autoimmune GFAP astrocytopathy patients with teratomas (serologic complexity). These findings suggest common pathogenesis of teratoma-associated CNS autoimmune diseases.

This study suggests that ovarian teratoma may trigger paraneoplastic NMOSD. Therefore, it is crucial to screen even young patients with NMOSD for tumors, particularly teratomas.
Acknowledgment

The authors thank Dr. Toshiyuki Takahashi (Department of Neurology, Tohoku University, Japan) for analyzing the AQP4-IgG and MOG-IgG, Dr. Akio Kimura (Department of Neurology, Gifu University Graduate School of Medicine, Japan) for analyzing the GFAPα-IgG, and Mizuho Karita for excellent technical assistance.

Study Funding

This work was supported in part by the Health and Labour Sciences Research Grant on Intractable Diseases (Neuromyelitis optica spectrum disorder) from the Ministry of Health, Labour and Welfare of Japan (20FC1030).

Disclosure

A. Shimomura, M. Suzuki, K. Shimoji, T. Motohashi, T. Yamamoto, N. Shibata, and K. Kitagawa report no disclosures relevant to the manuscript. R. Ikekuchi received honoraria for talks from Alexion Pharmaceuticals, Chugai Pharmaceutical Co, Ltd, and Novartis Pharma. Y. Shimizu received honoraria for talks from Alexion Pharmaceuticals, Bayer Yakuhin, and Chugai Pharmaceutical Co, Ltd; and personal compensation for consulting services from Biogen Idec Japan, Teijin Pharma, and Novartis Pharma. Go to Neurology.org/NN for full disclosures.

Publication History

Received by Neurology: Neuroimmunology & Neuroinflammation March 15, 2021. Accepted in final form May 24, 2021.

Appendix

Authors

<table>
<thead>
<tr>
<th>Name</th>
<th>Location</th>
<th>Contribution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ryotaro Ikekuchi, MD, PhD</td>
<td>Tokyo Women's Medical University, Tokyo, Japan</td>
<td>Design and conceptualized the study; analyzed the data; and drafted the manuscript for intellectual content</td>
</tr>
<tr>
<td>Yuko Shimizu, MD, PhD</td>
<td>Tokyo Women's Medical University, Tokyo, Japan</td>
<td>Design and conceptualized the study; analyzed the data; and drafted the manuscript for intellectual content</td>
</tr>
<tr>
<td>Ayato Shimomura, MD</td>
<td>Tokyo Women's Medical University, Tokyo, Japan</td>
<td>Analyzed the data and critically reviewed the manuscript</td>
</tr>
<tr>
<td>Miki Suzuki, MD, PhD</td>
<td>Tokyo Women's Medical University, Tokyo, Japan</td>
<td>Analyzed the data and critically reviewed the manuscript</td>
</tr>
<tr>
<td>Kanoko Shimoji, MD</td>
<td>Tokyo Women's Medical University, Tokyo, Japan</td>
<td>Analyzed the data and critically reviewed the manuscript</td>
</tr>
</tbody>
</table>

Table

Comparison of the Present Case and Previously Reported Cases

<table>
<thead>
<tr>
<th>Age at clinical onset/sex</th>
<th>1: Present case</th>
<th>2: Frasquet et al.5</th>
<th>3: Zoccarato et al.6,a</th>
<th>4: Bernard-Valnet et al.7 #1</th>
<th>5: Bernard-Valnet et al.7 #2</th>
<th>6: Bernard-Valnet et al.7 #3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Follow-up period, mo</td>
<td>27/F</td>
<td>42/F</td>
<td>50/F</td>
<td>15/F</td>
<td>21/F</td>
<td>48/F</td>
</tr>
<tr>
<td>Myelitis/optic neuritis/brainstem lesion</td>
<td>+/−/−</td>
<td>+/−/−</td>
<td>+/+/+</td>
<td>+/−/−</td>
<td>+/+/+</td>
<td>+/−/−</td>
</tr>
<tr>
<td>Nausea and/or vomiting</td>
<td>+</td>
<td>+</td>
<td>−</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>CSF pleocytosis/OCB</td>
<td>−/+</td>
<td>+/+</td>
<td>−/−</td>
<td>+/+</td>
<td>+/+</td>
<td></td>
</tr>
<tr>
<td>Dorsal brainstem lesion in MRI</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>−</td>
</tr>
<tr>
<td>Teratoma pathologyb</td>
<td>Neural tissue</td>
<td>+</td>
<td>NA</td>
<td>+</td>
<td>+</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Astrocytic gliosis</td>
<td>+</td>
<td>NA</td>
<td>+</td>
<td>+</td>
<td></td>
</tr>
<tr>
<td></td>
<td>AQP4 immunoreactivity</td>
<td>+</td>
<td>NA</td>
<td>+</td>
<td>+</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Complement deposition</td>
<td>+</td>
<td>NA</td>
<td>−</td>
<td>−</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Lymphocytic infiltration</td>
<td>+</td>
<td>NA</td>
<td>+</td>
<td>+</td>
<td></td>
</tr>
<tr>
<td>Relapse after removal of teratoma</td>
<td>−</td>
<td>−</td>
<td>+</td>
<td>−</td>
<td>−</td>
<td></td>
</tr>
<tr>
<td>Negative conversion of AQP4-IgG after removal of teratoma</td>
<td>−</td>
<td>NA</td>
<td>−</td>
<td>+</td>
<td>+</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: AQP4 = aquaporin-4; IgG = immunoglobulin G; NA = not available; NMOSD = neuromyelitis optica spectrum disorder; OCB = oligoclonal IgG band.

Detailed pathologic findings were available for 4 of 5 previously reported cases.5,7 Histopathologic analysis of the teratoma revealed a mature cystic teratoma in all 4 previously reported cases.

b This case developed NMOSD after the onset of anti-NMDAR encephalitis (5 mo after teratoma removal).6

b Removal of teratoma was performed in all 5 previously reported cases.5,7
References

Appendix (continued)

<table>
<thead>
<tr>
<th>Name</th>
<th>Location</th>
<th>Contribution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Takashi Motohashi, MD</td>
<td>Tokyo Women’s Medical University, Tokyo, Japan</td>
<td>Analyzed the data</td>
</tr>
<tr>
<td>Tomoko Yamamoto, MD, PhD</td>
<td>Tokyo Women’s Medical University, Tokyo, Japan</td>
<td>Analyzed the data and drafted the manuscript</td>
</tr>
<tr>
<td>Noriyuki Shibata, MD, PhD</td>
<td>Tokyo Women’s Medical University, Tokyo, Japan</td>
<td>Analyzed the data and drafted the manuscript</td>
</tr>
<tr>
<td>Kazuo Kitagawa, MD, PhD</td>
<td>Tokyo Women’s Medical University, Tokyo, Japan</td>
<td>Drafted the manuscript and critically reviewed the manuscript</td>
</tr>
</tbody>
</table>

6 Neurology: Neuroimmunology & Neuroinflammation | Volume 8, Number 5 | September 2021 | Neurology.org/NN
Paraneoplastic AQP4-IgG–Seropositive Neuromyelitis Optica Spectrum Disorder Associated With Teratoma: A Case Report and Literature Review
Ryotaro Ikeguchi, Yuko Shimizu, Ayato Shimomura, et al. 
*Neurol Neuroimmunol Neuroinflamm* 2021;8; DOI 10.1212/NXI.0000000000001045

This information is current as of July 20, 2021

**Updated Information & Services**
including high resolution figures, can be found at: 
http://nn.neurology.org/content/8/5/e1045.full.html

**References**
This article cites 12 articles, 3 of which you can access for free at: 
http://nn.neurology.org/content/8/5/e1045.full.html#ref-list-1

**Subspecialty Collections**
This article, along with others on similar topics, appears in the following collection(s): 
**Paraneoplastic syndrome** 
http://nn.neurology.org/cgi/collection/paraneoplastic_syndrome

**Permissions & Licensing**
Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: 
http://nn.neurology.org/misc/about.xhtml#permissions

**Reprints**
Information about ordering reprints can be found online: 
http://nn.neurology.org/misc/addir.xhtml#reprintsus